EGFR positive	Solid Tumor	EGFR positive	Solid Tumor	cetuximab Sensitive: C2 – Inclusion Criteria cetuximab Sensitive : C2	cetuximab Sensitive: C2 – Inclusion Criteria cetuximab Sensitive : C2
EGFR positive	Lung Cancer	EGFR positive	Lung Cancer	cetuximab Sensitive: C2 – Inclusion Criteria cetuximab Sensitive : C2	cetuximab Sensitive: C2 – Inclusion Criteria cetuximab Sensitive : C2
EGFR positive	Squamous Cell Carcinoma of Head and Neck	EGFR positive	Squamous Cell Carcinoma of Head and Neck	MRG003 Sensitive: C2 – Inclusion Criteria MRG003 Sensitive : C2	MRG003 Sensitive: C2 – Inclusion Criteria MRG003 Sensitive : C2
EGFR positive	Non Small Cell Lung Cancer	EGFR positive	Non Small Cell Lung Cancer	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2	aumolertinib Sensitive: C2 – Inclusion Criteria aumolertinib Sensitive : C2
EGFR positive	Non Small Cell Lung Cancer	EGFR positive	Non Small Cell Lung Cancer	gefitinib + anlotinib Sensitive: C3 – Early Trials gefitinib + anlotinib Sensitive : C3	gefitinib + anlotinib Sensitive: C3 – Early Trials gefitinib + anlotinib Sensitive : C3
EGFR positive	Nasopharyngeal Carcinoma	EGFR positive	Nasopharyngeal Carcinoma	MRG003 Sensitive: C3 – Early Trials MRG003 Sensitive : C3	MRG003 Sensitive: C3 – Early Trials MRG003 Sensitive : C3
EGFR positive	Breast Cancer	EGFR positive	Breast Cancer	cetuximab Sensitive: D – Preclinical cetuximab Sensitive : D	cetuximab Sensitive: D – Preclinical cetuximab Sensitive : D
EGFR positive	Hepatocellular Cancer	EGFR positive	Hepatocellular Cancer	cetuximab Sensitive: D – Preclinical cetuximab Sensitive : D	cetuximab Sensitive: D – Preclinical cetuximab Sensitive : D

EGFR positive

Associations